DV
Dividend Vision

HRTX — Heron Therapeuti

Heron Therapeuti (HRTX)

Its deepest 1-year drawdown was 78.3%.

Heron Therapeutics is a commercial-stage biotechnology company developing and commercializing injectable therapeutics for nausea, vomiting, and pain management, including marketed products SUSTOL and CINVANTI for chemotherapy-induced symptoms and pipeline candidates ZYNRELEF and APONVIE. The company does not currently distribute dividends. This stock appeals to investors seeking exposure to biotechnology development and commercialization rather than current income.

HRTX key facts

Asset type
Stock
Asset class
Equity
Inception date
08/26/1987
Last close
$0.34
Market cap
$90,929,808
Average volume
1762099.0
Beta
1.651
Payout ratio
0.0
Forward P/E
46.9484
EPS
$-0.18